Dr. Wu Yilong

Honorary President of Guangdong Lung Cancer Institute; Chief Physician; Professor

Internationally recognized as a pioneer of precision medicine for lung cancer in Asia; led the landmark IPASS trial that established EGFR-TKI as first-line therapy for EGFR-mutant non-small cell lung cancer, fundamentally changing global treatment guidelines; past president of the Chinese Thoracic Oncology Group (CTONG); published in NEJM, The Lancet, JCO

One of the most sought-after lung cancer specialists in Asia. Best suited for patients with driver-mutation-positive lung cancer seeking expert guidance on targeted therapy sequencing.

Research this doctor's background on trusted platforms.

Results are automated searches and may include other individuals with similar names.